Delafloxacin meglumine | CAS# 352458-37-8 | Antibiotic

MedKoo Cat#: 524947 | Name: Delafloxacin meglumine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Delafloxacin is a fluoroquinolone antibiotic agent. Delafloxacin meglumine is more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. In vitro: Delafloxacin meglumine exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs

Chemical Structure

Delafloxacin meglumine

CAS#352458-37-8 (meglumine)

Theoretical Analysis

MedKoo Cat#: 524947

Name: Delafloxacin meglumine

CAS#: 352458-37-8 (meglumine)

Chemical Formula: C25H29ClF3N5O9

Exact Mass: 0.0000

Molecular Weight: 635.98

Elemental Analysis: C, 47.21; H, 4.60; Cl, 5.57; F, 8.96; N, 11.01; O, 22.64

Price and Availability

Size	Price	Availability
100mg	USD 350.00	2 Weeks
250mg	USD 700.00	2 Weeks
500mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

189279-58-1 (free acid) 352458-37-8 (meglumine)

Synonym

Delafloxacin meglumine; ABT-492; ABT 492; ABT492; RX-3341; RX 3341; RX3341; WQ-3034; WQ 3034; WQ3034; Baxdela.

IUPAC/Chemical Name

(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1:1)

InChi Key

AHJGUEMIZPMAMR-WZTVWXICSA-N

InChi Code

InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES Code

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(C1=CN(C2=NC(N)=C(F)C=C2F)C3=C(C=C(F)C(N4CC(O)C4)=C3Cl)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic that has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia.

In vitro activity:

Delafloxacin exhibited excellent in vitro activity against 117 N. gonorrhoeae strains (110 clinical N. gonorrhoeae isolates and 7 GISP reference strains). In general, MICs of delafloxacin (≤0.001 to 0.25 μg/ml) were lower than those of 5 comparator antimicrobials but comparable to those of ceftriaxone (≤0.001 to 0.25 μg/ml) and cefixime (≤0.001 to 0.5 μg/ml) (Table 1). The highest delafloxacin MIC observed was 0.25 μg/ml in a single clinical isolate. Although resistant mutants arose at a frequency between 1.7 × 10−7 and 8.9 × 10−8 at 2× the original delafloxacin MICs for the other two ciprofloxacin-resistant N. gonorrhoeae strains (13199 and 131011), the mutation frequencies were below the limit of detection at 4×, 8×, and 16× the MIC (<1.4×10−9 to <1.6×10−9) (Table 2). The multistep delafloxacin resistance selection of 30 daily passages resulted in mutants with 8-fold to 16-fold increases in delafloxacin MICs (Table 3). In conclusion, delafloxacin was highly active against clinical N. gonorrhoeae isolates with diverse antimicrobial susceptibility profiles, including isolates with high-level ciprofloxacin resistance, high-level azithromycin resistance, reduced cephalosporin susceptibility, and multidrug resistance Reference: Antimicrob Agents Chemother. 2016 May; 60(5): 3106–3111. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862482/

In vivo activity:

The objectives of our experiments were to characterize the in vivo efficacy of delafloxacin using a neutropenic murine lung infection model for three common respiratory tract pathogen groups, including S. aureus, S. pneumoniae, and K. pneumoniae. At the doses studied, exposure to delafloxacin increased in a dose-dependent manner across the dose range. Cmax concentrations ranged from 2 to 71 mg/liter. AUC0–∞ values ranged from 2.8 to 152 mg h/liter and were linear across the 2.5- to 160-mg dosing range (R2 of 0.99). Delafloxacin was highly effective against S. aureus (Fig. 2A). Against all four strains we observed a decrease of 1.5 to 2.2 log10 CFU in organism burden from untreated controls at even the lowest dose studied, and for two strains (MW2 and R2527) there was net bactericidal activity at the lowest dose. At the maximal doses studied, there was a >4-log10 kill from initial burden for all S. aureus strains. Likewise, delafloxacin was very potent against S. pneumoniae (Fig. 2B). The data presented will be useful for delafloxacin dosing regimen optimization for the treatment of respiratory tract infections and for setting the preliminary breakpoints. Reference: Antimicrob Agents Chemother. 2016 Aug; 60(8): 4764–4769. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958193/

	Solvent	mg/mL	mM
Solubility
	DMSO	39.0	61.32
	H2O	75.0	117.93

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 635.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. PMID: 27458220; PMCID: PMC5038254. 2. Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3106-11. doi: 10.1128/AAC.02798-15. PMID: 26976873; PMCID: PMC4862482. 3. Lepak AJ, Andes DR. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764- 9. doi: 10.1128/AAC.00647-16. PMID: 27216072; PMCID: PMC4958193.

In vitro protocol:

In vivo protocol:

1. Lepak AJ, Andes DR. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764- 9. doi: 10.1128/AAC.00647-16. PMID: 27216072; PMCID: PMC4958193.

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548907/ PubMed PMID: 31644214. 2: Koeth LK, DiFranco-Fisher JM, Hardy DJ, Mortensen JE, Palavecino E, Windau AW. Multilab evaluation of delafloxacin MIC Test Strip against Gram-negative and Gram-positive organisms. Diagn Microbiol Infect Dis. 2019 Nov;95(3):114868. doi: 10.1016/j.diagmicrobio.2019.07.006. Epub 2019 Jul 30. PubMed PMID: 31447245. 3: Iregui A, Khan Z, Malik S, Landman D, Quale J. Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY. Clin Infect Dis. 2019 Aug 15. pii: ciz787. doi: 10.1093/cid/ciz787. [Epub ahead of print] PubMed PMID: 31412357. 4: Zhao M, Lepak AJ, Marchillo K, Andes DR. In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01131-19. doi: 10.1128/AAC.01131-19. Print 2019 Oct. PubMed PMID: 31332063; PubMed Central PMCID: PMC6761510. 5: Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 May 27;12:1415-1423. doi: 10.2147/IDR.S202160. eCollection 2019. PubMed PMID: 31213859; PubMed Central PMCID: PMC6549389. 6: Hook EW 3rd, Golden MR, Taylor SN, Henry E, Tseng C, Workowski KA, Swerdlow J, Nenninger A, Cammarata S. Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study. Sex Transm Dis. 2019 May;46(5):279-286. doi: 10.1097/OLQ.0000000000000971. PubMed PMID: 30985632. 7: Bassetti M, Hooper D, Tillotson G. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S233-S240. doi: 10.1093/cid/ciy1080. PubMed PMID: 30957169; PubMed Central PMCID: PMC6451993. 8: Giordano PA, Pogue JM, Cammarata S. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S223-S232. doi: 10.1093/cid/ciz006. PubMed PMID: 30957167; PubMed Central PMCID: PMC6452004. 9: Tulkens PM, Van Bambeke F, Zinner SH. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S213-S222. doi: 10.1093/cid/ciy1079. PubMed PMID: 30957164; PubMed Central PMCID: PMC6452001. 10: Corey GR, McKinnell JA, Rybak MJ. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S191-S192. doi: 10.1093/cid/ciy1089. PubMed PMID: 30957163; PubMed Central PMCID: PMC6451998. 11: Hook EW 3rd, Golden MR, Taylor SN, Henry E, Tseng C, Swerdlow J, Nenninger A, Cammarata S. Efficacy and safety of single dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, non-inferiority, Phase 3, multicenter, randomized study. Sex Transm Dis. 2019 Jan 19. doi: 10.1097/OLQ.0000000000000971. [Epub ahead of print] PubMed PMID: 30676487. 12: Kaul G, Kapoor E, Dasgupta A, Chopra S. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Drugs Today (Barc). 2018 Nov;54(11):657-666. doi: 10.1358/dot.2018.54.11.2878151. Review. PubMed PMID: 30539165. 13: Adler A, Chaudhry S, Goldberg T. Baxdela(TM) (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections. P T. 2018 Nov;43(11):662-666. PubMed PMID: 30410281; PubMed Central PMCID: PMC6205123. 14: Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infect Dis. 2018 Sep 10;5(10):ofy220. doi: 10.1093/ofid/ofy220. eCollection 2018 Oct. PubMed PMID: 30349845; PubMed Central PMCID: PMC6189306. 15: Shiu J, Ting G, Kiang TK. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin. Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):305-317. doi: 10.1007/s13318-018-0520-8. Review. PubMed PMID: 30324277. 16: Markham A. Correction to: Delafloxacin: First Global Approval. Drugs. 2018 Oct;78(15):1651. doi: 10.1007/s40265-018-0990-7. PubMed PMID: 30284698; PubMed Central PMCID: PMC6208763. 17: Eudaley S. Delafloxacin (Baxdela) for Skin Infections. Am Fam Physician. 2018 Aug 15;98(4):246-247. PubMed PMID: 30215969. 18: Saravolatz LD, Stein GE. Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clin Infect Dis. 2019 Mar 5;68(6):1058-1062. doi: 10.1093/cid/ciy600. PubMed PMID: 30060092. 19: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500923/ PubMed PMID: 29999982. 20: Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2018 Jul;16(7):523-530. doi: 10.1080/14787210.2018.1489721. Epub 2018 Jun 26. Review. PubMed PMID: 29911455.